| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| Other Sizes |
| Targets |
3-Oxo-5β-cholanoic acid sodium targets the transcription factor RORγt (retinoic acid receptor-related orphan receptor gamma t), a key regulator of TH17 cell differentiation. RORγt is a nuclear receptor that controls the expression of pro-inflammatory cytokines such as IL-17A. By directly binding to RORγt with a Kd of 1.13 μM, 3-oxo-5β-cholanoic acid sodium inhibits TH17 cell differentiation. This mechanism of action is relevant for the regulation of immune responses and for the study of autoimmune and inflammatory diseases.
|
|---|---|
| ln Vitro |
3-Oxo-5β-cholanoic acid sodium exhibits in vitro activity as a RORγt ligand and inhibitor of TH17 cell differentiation. It binds directly to RORγt with a Kd of 1.13 μM. In cellular assays, the compound inhibits the differentiation of naïve T cells into TH17 cells, as assessed by measuring the production of IL-17A and the expression of RORγt target genes. These in vitro activities confirm its potential as a research tool for studying TH17-mediated immune responses and for developing therapies for autoimmune diseases.
|
| ln Vivo |
In vivo activity of 3-Oxo-5β-cholanoic acid sodium has been studied in animal models of autoimmune and inflammatory diseases. As a RORγt inhibitor, the compound suppresses TH17 cell differentiation and reduces IL-17 production in vivo. This may have therapeutic potential for diseases such as multiple sclerosis, psoriasis, and inflammatory bowel disease. However, detailed in vivo data are limited, as the compound is primarily used as a research tool. Further studies are needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
In vitro binding assays for 3-Oxo-5β-cholanoic acid sodium involve measuring its affinity for RORγt. Surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC) are typically used to determine the dissociation constant (Kd) of 1.13 μM. In these assays, recombinant RORγt protein is immobilized, and the compound is flowed over the surface to measure binding kinetics. Competitive binding assays with fluorescently labeled RORγt ligands can also be used to confirm target engagement. These assays confirm the compound's mechanism as a RORγt ligand.
|
| Cell Assay |
In vitro cellular assays for 3-Oxo-5β-cholanoic acid sodium are conducted in T cell cultures, where naïve T cells are differentiated into TH17 cells in the presence of the compound. TH17 cell differentiation is assessed by measuring the production of IL-17A by ELISA or flow cytometry. The expression of RORγt target genes is measured by qPCR. Cell viability is assessed to ensure that observed effects are not due to cytotoxicity. These assays characterize the compound's activity as an inhibitor of TH17 cell differentiation.
|
| Animal Protocol |
In vivo animal experiments with 3-Oxo-5β-cholanoic acid sodium are conducted in mouse models of autoimmune diseases, such as experimental autoimmune encephalomyelitis (EAE) or colitis. The compound is administered orally or by intraperitoneal injection at varying doses. Disease severity is assessed by clinical scores, histopathology, and inflammatory cytokine levels. TH17 cell frequency and IL-17 production are measured in lymphoid tissues. These studies evaluate the compound's efficacy in suppressing TH17-mediated autoimmune inflammation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 3-Oxo-5β-cholanoic acid sodium are limited. The compound has a molecular weight of 390.56 and is soluble in DMSO. It is a metabolite of lithocholic acid, and its pharmacokinetics are related to bile acid metabolism. The compound is typically stored at 4°C. Further PK studies would be needed to support any potential clinical development.
|
| Toxicity/Toxicokinetics |
3-Oxo-5β-cholanoic acid sodium is considered to have low toxicity based on its use as a research compound and its occurrence as a natural bile acid metabolite. However, comprehensive toxicological evaluations have not been extensively published. The compound is intended for research use only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
3-Oxo-5β-cholanoic acid sodium is the sodium salt of 3-ketolithocholic acid, a major metabolite of lithocholic acid (LCA). It is also known as dehydrolithocholic acid. This bile acid metabolite functions as an inhibitor of TH17 cell differentiation by directly binding to the key transcription factor RORγt (Kd=1.13 μM). It is available in high purity (≥98%) for research applications. Its role in immune regulation makes it a valuable tool for studying autoimmune and inflammatory diseases.
|
| Appearance |
Typically exists as solid at room temperature
|
|---|---|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
